Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome

• Main Authors: Ibrahim Knani (Author), Brian J. Earley (Author), Shiran Udi (Author), Alina Nemirovski (Author), Rivka Hadar (Author), Asaad Gammal (Author), Resat Cinar (Author), Harry J. Hirsch (Author), Yehuda Pollak (Author), Itai Gross (Author), Talia Eldar-Geva (Author), Daniela P. Reyes-Capo (Author), Joan C. Han (Author), Andrea M. Haqq (Author), Varda Gross-Tsur (Author), Rachel Wevrick (Author), Joseph Tam (Author)
• Format: Book
• Published: Elsevier, 2016-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Extreme obesity is a core phenotypic feature of Prader-Willi syndrome (PWS). Among numerous metabolic regulators, the endocannabinoid (eCB) system is critically involved in controlling feeding, body weight, and energy metabolism, and a globally acting cannabinoid-1 receptor (CB1R) blockad...